Moreover, EGFR activation increases PAFR and LPCAT2 expression, and a significantly greater effect was noted in highly aggressive ovarian cancer CASKI cells compared to less aggressive C33A cells. This evidence concerns the gene EGFR and ovarian carcinoma.